SOMATOSTATIN RECEPTORS SCINTIGRAPHY PRIORITIZATION CRITERIA BASED ON NET PATIENT EPIDEMIOLOGICAL PROFILE: A BI-CENTRIC STUDY
This study aimed to create a generic profile of patients with NETs and to establish the prioritization criteria for somatostatin receptors scintigraphy (SRS), within the NETs diagnostic algorithm, being the first study of this kind conducted in Romania. Material and methods: A bi-centric, retro-prospective study comprising 103 patients with NETs, evaluated through 99mTc-TOC SRS, in two nuclear medicine departments from “Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania and Center of Nuclear Medicine, University Clinical Center of Kragujevac, Serbia. We analyzed the clinical-paraclinical features of included patients, as a starting point for streamlining the selection of patients for SRS. Results and discussion: The total group of patients included 47.57 % men and 52.43 % women, the age varying between 21-83 years. The most frequent primary NETs were represented by pNETs, and GI-NETs and the symptoms were nonspecific for majority of analyzed patients. Both prospective and retrospective analysis showed that SRS was followed by positive results. For prospectively analyzed patients, due to the used customized sheets, it was extremely easy to identify four SRS prioritization criteria. Conclusions: This study could outline the profile of patients with NETs, as the starting point for streamlining patient selection for SRS. The four prioritization criteria proposed by us could guide the diagnostic algorithm.
2. Stolniceanu CR, Nistor I, Bilha SC, et al. Nephrotoxicity/renal failure after therapy with 90Ytrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nucl Med Commun 2020; 41(7): 601-617 / doi: 10.1097/MNM.0000000000001198.
3. Balon HR, Brown TL, Goldsmith SJ, et al. Society of Nuclear Medicine. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol 2011; 39: 317-324.
4. Darbà J, Marsà A. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources. BMC Cancer 2019; 19(1): 1226 / doi: 10.1186/s12885-019-6412-8.
5. Kilickap S, Hayran KM. Epidemiology of Neuroendocrine Tumors. In: Yalcin S, Öberg K, editors. Neuroendocrine Tumours. Berlin, Heidelberg: Springer-Verlag, 2015.
6. Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021; 23(4): 43 / doi: 10.1007/s11912-021-01029-7.
7. van der Zwan JM, Trama A, Otter R, et al. Rare neuroendocrine tumors: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer 2013; 49(11): 2565-2578.
8. Santos A, Santos A, Castro C, et al. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers 2018; 10(9): 293 / doi: 10.3390/cancers10090293.
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
N.B. All the authors must sign this form